 Here we designed the first placebo-controlled, double blinded randomized trial in the use of flexible-dose amitriptyline tricyclic antidepressant for the treatment of neuropathic pain related to leprosy. This study is currently approved by our local Ethics Review Board CAAE: 45393415.9.0000.0068 and has stared the recruitment phase on March 2017. 